Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96AA3
UPID:
RFT1_HUMAN
Alternative names:
-
Alternative UPACC:
Q96AA3; Q96J03
Background:
Protein RFT1 homolog plays a pivotal role in the assembly of N-linked oligosaccharides, a process crucial for protein folding and stability. It is involved in the translocation of oligosaccharides across the endoplasmic reticulum membrane, highlighting its essential function in cellular machinery.
Therapeutic significance:
The protein's link to Congenital disorder of glycosylation 1N, a condition marked by a wide array of clinical manifestations including developmental and immunological defects, underscores its therapeutic potential. Targeting the protein could lead to novel treatments for this glycosylation disorder, offering hope for affected individuals.